Clinical trials: Infusions, Intravenous
Type 2 Diabetes Mellitus
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on treatment assignment in young healthy male…
- Trial name
- NCT02012166
- Testing
- MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting (CINV)
QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration
This is a single-center, single-dose, randomized, open-label, crossover study. Forty-two healthy male and female participants will be enrolled.
- Trial name
- NCT07817004
- Testing
- apripitant and palonosetron injectable emulsion, palonosetron hydrochloride injection, apripitant injection (CINVANTI)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Healthy
The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects
This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants.
- Trial name
- NCT05085197
- Testing
- STSA-1005 injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Staidson Biopharma Inc.
Healthy Volunteers
An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)
The primary objective of Part 1 of this study is to evaluate the safety and tolerability of the intravenous (IV) dose of GDC-0973.
- Trial name
- NCT01249118
- Testing
- GDC-0973 IV Infusion, GDC-0973 Oral Capsules
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects
Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects
- Trial name
- NCT01671020
- Testing
- Fimasartan
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Healthy
A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
This study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over single-dose study to test the absolute bioavailability of oral crizotinib formulation to IV formulation in healthy adult volunteers.
- Trial name
- NCT01168934
- Testing
- crizotinib
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.
- Trial name
- NCT04564066
- Testing
- efgartigimod IV, efgartigimod PH20 SC
- Where
- Netherlands
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- argenx
Diabetes Mellitus
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
- Trial name
- NCT00287066
- Testing
- Inhaled Human Insulin, Regular Human Insulin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Safety Issues
A Phase1 Study of VIB9600
Overall design: Single-center, randomized, blinded, placebo-controlled single- and multiple-ascending dose study in healthy adult subjects.
- Trial name
- NCT03621605
- Testing
- VIB9600
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Acute Pain
Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography
The goal of this clinical trial is to learn if oxytocin reduces pain in a small area of skin after pulses of non-burning heat by changing how nerves in the heated area react to pressing a thin, bendable plastic bristle and a…
- Trial name
- PAINOXY (NCT07409753)
- Testing
- Intravenous Oxytocin
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Postoperative Pain Management After Total Hip Arthroplasty
Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion
This study will focus on patients undergoing total hip arthroplasty and Loma Linda University Medical Center \& East Campus. These patients will be randomized to receive a low dose lidocaine infusion or placebo, in addition to…
- Trial name
- NCT01108562
- Testing
- Lidocaine, Normal Saline
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Healthy Volunteers
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of NH302 Injection in Healthy Participants
This is a first-in-human study of NH302 injection in healthy participants. The study will test single intravenous doses of NH302 to evaluate its safety and tolerability, how the body processes NH302, and its effects on selected…
- Trial name
- NCT07892469
- Testing
- NH302 injection
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Healthy
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
The purpose of this study is to gain an understanding of how the experimental anti-cancer drug, rigosertib, is metabolized in the body and excreted in the urine and feces after it is given as an intravenous infusion.
- Trial name
- NCT02030639
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Traws Pharma, Inc.
HIV Infections
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or…
- Trial name
- NCT04212091
- Testing
- PGT121.414.LS, VRC07-523LS
- Where
- 5 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and…
- Trial name
- NCT03554408
- Testing
- 10-1074-LS, 3BNC117-LS
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Asthma, Healthy
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
- Trial name
- NCT00638989
- Testing
- CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Lung Injury, Acute
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers
This study is a single dose evaluation using an open label dose escalating design. Cohort1 will consist of 3 healthy male volunteers.
- Trial name
- NCT01640990
- Testing
- Saline, GW328267X (total dose of 12mcg), GW328267X (total dose of 40mcg)
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heathly Subjects
Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects
1. Part 1 Randimization, Double blinded, Placebo controlled, Dose escalation(10mg, 20mg, 40mg) of MIT-001 SC or IV single administration to evaluate safety, tolerability and PK in healthy adult. 2.
- Trial name
- NCT05389696
- Testing
- Single subcutaneous administration and Blood collection, Single subcutaneous administration and then IV injection., MIT-001 20mg and 40mg_Multiple administration
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MitoImmune Therapeutics
Drug Interactions
Effect of Itraconazole on the Pharmacokinetics of Intravenous HRS-4642 in Healthy Participants
This is a Phase 1, single-center, open-label study designed to evaluate the effect of itraconazole on the pharmacokinetics of HRS-4642 in healthy adult participants. Approximately 18 healthy participants will be enrolled.
- Trial name
- NCT07894679
- Testing
- HRS-4642, Itraconazole (200 mg)
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Healthy
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
The primary purpose of this study is to assess the safety and tolerability of AZD3043 following administration of single ascending bolus doses (Part A) and single ascending bolus doses followed by infusion (Part B).
- Trial name
- NCT00984880
- Testing
- AZD3043
- Where
- Sweden
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca